skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
Indication-based pricing isn’t just coming. It’s here. Drug companies have historically priced drugs equally across indications, regardless of the variation in value. But using indication-specific pricing, payers – and PBMs in particular – see a new opportunity to break the market-share dominance of several key therapeutics, boost their near-term rebate and distribution income, and re-shape traditional contracting.

Indication-Based Pricing

Download your free article pack, to discover new insights into indication-based pricing
Market access_RxScorecard_Pharmaintelligence

Read also

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: